MEAGAN GILBERT: Open Payments
NPI 1457753410 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,893 in 122 payments from 19 companies in 2025. Trend: 2023 $1,104 · 2024 $2,198 · 2025 $2,893
Food & beverage: $2,809Education: $84
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 19 | $656 |
| ABBVIE INC. | 21 | $534 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $389 |
| Madrigal Pharmaceuticals | 6 | $164 |
| GENZYME CORPORATION | 6 | $147 |
| Aimmune Therapeutics, Inc. | 7 | $137 |
| Phathom Pharmaceuticals, Inc. | 6 | $132 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $118 |
| Regeneron Healthcare Solutions, Inc. | 5 | $114 |
| Celltrion USA Inc. | 5 | $101 |
Products named: TREMFYA, ENTYVIO, RINVOQ, SKYRIZI, DUPIXENT, REZDIFFRA, VOQUEZNA, XIFAXAN.
Industry payments across TX — which companies pay providers there.
